X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs ALEMBIC PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD ALEMBIC PHARMA WYETH LTD/
ALEMBIC PHARMA
 
P/E (TTM) x 27.7 27.0 102.8% View Chart
P/BV x 5.3 5.4 98.4% View Chart
Dividend Yield % 1.3 0.6 204.0%  

Financials

 WYETH LTD   ALEMBIC PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
ALEMBIC PHARMA
Mar-18
WYETH LTD/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044645 161.9%   
Low Rs818470 174.1%   
Sales per share (Unadj.) Rs298.6166.1 179.8%  
Earnings per share (Unadj.) Rs57.221.9 261.4%  
Cash flow per share (Unadj.) Rs58.427.5 212.5%  
Dividends per share (Unadj.) Rs17.004.00 425.0%  
Dividend yield (eoy) %1.80.7 254.4%  
Book value per share (Unadj.) Rs249.5117.8 211.8%  
Shares outstanding (eoy) m22.72188.52 12.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.4 92.9%   
Avg P/E ratio x16.325.5 63.9%  
P/CF ratio (eoy) x15.920.3 78.6%  
Price / Book Value ratio x3.74.7 78.9%  
Dividend payout %29.718.3 162.6%   
Avg Mkt Cap Rs m21,157105,090 20.1%   
No. of employees `0000.5NA-   
Total wages/salary Rs m4006,228 6.4%   
Avg. sales/employee Rs Th13,787.4NM-  
Avg. wages/employee Rs Th813.0NM-  
Avg. net profit/employee Rs Th2,643.3NM-  
INCOME DATA
Net Sales Rs m6,78331,308 21.7%  
Other income Rs m35370 501.6%   
Total revenues Rs m7,13631,378 22.7%   
Gross profit Rs m1,6176,431 25.1%  
Depreciation Rs m271,055 2.5%   
Interest Rs m634 16.2%   
Profit before tax Rs m1,9385,413 35.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6321,204 52.5%   
Profit after tax Rs m1,3014,128 31.5%  
Gross profit margin %23.820.5 116.1%  
Effective tax rate %32.622.2 146.7%   
Net profit margin %19.213.2 145.4%  
BALANCE SHEET DATA
Current assets Rs m6,98418,247 38.3%   
Current liabilities Rs m2,05611,235 18.3%   
Net working cap to sales %72.622.4 324.3%  
Current ratio x3.41.6 209.2%  
Inventory Days Days9986 116.0%  
Debtors Days Days2461 39.0%  
Net fixed assets Rs m24420,035 1.2%   
Share capital Rs m227377 60.3%   
"Free" reserves Rs m5,44121,824 24.9%   
Net worth Rs m5,66822,201 25.5%   
Long term debt Rs m255,000 0.5%   
Total assets Rs m7,90139,411 20.0%  
Interest coverage x353.3160.2 220.6%   
Debt to equity ratio x00.2 2.0%  
Sales to assets ratio x0.90.8 108.1%   
Return on assets %16.510.6 156.5%  
Return on equity %22.918.6 123.4%  
Return on capital %34.019.7 172.6%  
Exports to sales %0.246.4 0.5%   
Imports to sales %36.310.5 346.0%   
Exports (fob) Rs m1514,535 0.1%   
Imports (cif) Rs m2,4653,288 75.0%   
Fx inflow Rs m1514,722 0.1%   
Fx outflow Rs m2,6777,026 38.1%   
Net fx Rs m-2,6627,696 -34.6%   
CASH FLOW
From Operations Rs m9233,124 29.5%  
From Investments Rs m317-8,844 -3.6%  
From Financial Activity Rs m-4815,026 -9.6%  
Net Cashflow Rs m759-693 -109.5%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 2.9 389.7%  
FIIs % 7.2 9.1 79.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 13.9 218.7%  
Shareholders   21,978 49,328 44.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT LTD.  SUVEN LIFE  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - DIVIS LABORATORIES COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS